Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Common Equity: 2020-2024

Historic Common Equity for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $26.0 million.

  • SAB Biotherapeutics' Common Equity rose 347.32% to $165.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.1 million, marking a year-over-year increase of 347.32%. This contributed to the annual value of $26.0 million for FY2024, which is 54.68% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Common Equity stood at $26.0 million for FY2024, which was down 54.68% from $57.3 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Common Equity peaked at $57.3 million during FY2023, and registered a low of $26.0 million during FY2024.
  • Its 3-year average for Common Equity is $38.1 million, with a median of $31.1 million in 2022.
  • Per our database at Business Quant, SAB Biotherapeutics' Common Equity surged by 84.49% in 2023 and then tumbled by 54.68% in 2024.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Common Equity stood at $39.0 million in 2020, then dropped by 1.17% to $38.5 million in 2021, then decreased by 19.43% to $31.1 million in 2022, then soared by 84.49% to $57.3 million in 2023, then slumped by 54.68% to $26.0 million in 2024.